Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
This study investigates whether the response criteria proposed by the European LeukemiaNet (ELN) to evaluate cytoreductive therapies in essential thrombocythemia (ET) correlate with clinically relevant outcomes in patients receiving anagrelide. We evaluated 154 ET patients treated with anagrelide (upfront in 87) for a median of 2.9 years. Complete response (CR), partial response, and no response were observed in 56, 30.5, and 13.5 % patients, respectively. Only 38 patients (25 %) achieved a sustained CR. Overall, the aggregated time on CR and without CR was 200.1 and 333.6 person-years, respectively. The incidence rate of thrombosis and hemorrhage was independent of the CR status. The only factor associated with shorter survival after anagrelide start was the patient's age, whereas achieving a CR with anagrelide had no predictive value for subsequent survival. In conclusion, CR according to the ELN definition is not associated with any measurable clinical benefit in ET patients treated with anagrelide.
Hematology and Medical Oncology Department, Hospital Clínico Universitario, Avd. Blasco Ibáñez 17, 46010, Valencia, Spain. hernandez_jca@gva.es
Juan Carlos
JC
Hernández-Boluda
Arturo
A
Pereira
Francisco
F
Cervantes
Montse
M
Gómez
Eduardo
E
Arellano-Rodrigo
Alberto
A
Alvarez-Larrán
Francisca
F
Ferrer-Marín
Ana
A
Kerguelen
José Antonio
JA
Márquez
María Luisa
ML
Antelo
Carles
C
Besses
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007372:Interferons / Q000627:therapeutic use; D007390:International Agencies / Q000592:standards*; D053208:Kaplan-Meier Estimate; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009929:Organ Size / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D013030:Spain / Q000453:epidemiology; D013154:Spleen / Q000473:pathology*; D016019:Survival Analysis; D013920:Thrombocythemia, Essential / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult
D015415:Biomarkers; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; D007372:Interferons; C021139:anagrelide; D006918:Hydroxyurea